clarithromycin has been researched along with cyclosporine in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (25.00) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, T; Hui, CS; Kitaichi, K; Miyamoto, KI; Sakai, M; Takagi, K; Wang, L; Yokogawa, K | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blanco, MJ; Edmondson, Q; Furukawa, A; Handford, MJ; Hewitt, WM; Kelly, CN; Klein, VG; Lokey, RS; Ly, AM; Naylor, MR; Noland, RP; Pye, CR; Ramos, DP; Schwochert, J; Townsend, CE; Turmon, AC | 1 |
| Iwamoto, K; Morikawa, K; Morikawa, S; Oseko, F | 1 |
| Ferrari, SL; Goffin, E; Mourad, M; Pirson, Y; Squifflet, JP; Wallemacq, P | 1 |
| Abramowicz, D; Demol, H; Quoidbach, A; Treille, S; Vereerstraeten, P | 1 |
| Iwakawa, S; Komada, F; Ohba, M; Ohnishi, N; Okumura, K | 1 |
| Barclay, P; Chapman, JR; Liddle, C; Nankivell, BJ; O'Connell, PJ; Spicer, ST; Thomas, P | 1 |
| Garces, MC; McAllister, CK; Plemmons, RM; Ward, RL | 1 |
| Alvarez-Grande, J; Gómez, E; Portal, C; Sánchez, JE; Sánchez-Nuñez, ML | 1 |
| Azanza, JR; Cienfuegos, JA; López de Ocáriz, A; Quiroga, J; Sádaba, B | 1 |
| Kantrow, SP; Knower, MT; Labella-Walker, K; McFadden, PM; Valentine, VG | 1 |
| Ashihara, E; Fujita, N; Hatsuse, M; Inaba, T; Nakagawa, M; Noda, Y; Ochiai, N; Okano, A; Shimazaki, C; Takahashi, R | 1 |
| Bartoli, F; Castronovo, G; De Iudicibus, S; Decorti, G; Di Lenarda, R; Gigante, A; Stocco, G | 1 |
| Kamishina, H; Katayama, M; Katayama, R; Nishijima, N; Okamura, Y; Uzuka, Y; Yamashita, T | 1 |
| Katayama, M; Katayama, R; Kawakami, Y; Okamura, Y; Shimamura, S; Uzuka, Y | 1 |
| Gota, V; Mehta, M; Patel, K; Patil, A; Vavia, P | 1 |
| Das, T; Foroutan, P; Gatenby, RA; Gillies, RJ; Kam, Y; Martinez, G; Minton, S; Ruiz, E; Tian, H | 1 |
| Kishimoto, K; Matsuse, H; Nakayama, H; Oshio, T | 1 |
| Damanhuri, NS; Kumolosasi, E; Mansor, AH; Omar, MS; Razak, AFA | 1 |
2 review(s) available for clarithromycin and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Clarithromycin; Combined Modality Therapy; Cyclosporine; Debridement; Drug Therapy, Combination; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Methotrexate; Minocycline; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Skin Ulcer; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous | 2001 |
1 trial(s) available for clarithromycin and cyclosporine
| Article | Year |
|---|---|
The mechanism of cyclosporine toxicity induced by clarithromycin.
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Breath Tests; Carbon Radioisotopes; Clarithromycin; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Oxidoreductases, N-Demethylating; Reference Values | 1997 |
29 other study(ies) available for clarithromycin and cyclosporine
| Article | Year |
|---|---|
Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Membrane; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Immunosuppressive Agents; Leukemia P388; Macrolides; Mice; Neoplasm Transplantation; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
Topics: 1-Octanol; Cell Membrane Permeability; Cyclosporins; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Peptides; Peptides, Cyclic; Pharmaceutical Preparations; Small Molecule Libraries; Solubility; Structure-Activity Relationship; Water | 2018 |
Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Cell Division; Cell Survival; Clarithromycin; Cyclosporine; Humans; Interleukin-2; Josamycin; Kinetics; Leucomycins; Leukocytes, Mononuclear; Receptors, Interleukin-2; Stimulation, Chemical; T-Lymphocytes; Tacrolimus | 1994 |
The interaction between clarithromycin and cyclosporine in kidney transplant recipients.
Topics: Adult; Clarithromycin; Creatinine; Cyclosporine; Drug Interactions; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged | 1994 |
Kidney graft dysfunction after drug interaction between clarithromycin and cyclosporin.
Topics: Adult; Clarithromycin; Cyclosporine; Drug Interactions; Female; Humans; Kidney; Kidney Transplantation | 1996 |
Effect of clarithromycin on the bioavailability of cyclosporin in rats.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Biological Availability; Clarithromycin; Cyclosporine; Cyclosporins; Drug Interactions; Erythromycin; Gastric Emptying; Infusions, Intravenous; Male; Rats; Rats, Wistar | 1996 |
Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine.
Topics: Adult; Clarithromycin; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Mycobacterium haemophilum; Mycobacterium Infections; Osteomyelitis; Rifampin | 1997 |
Clarithromycin in the treatment of cyclosporin-associated gingival hyperplasia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Cyclosporine; Female; Gingival Hyperplasia; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged | 1997 |
Concurrent clarithromycin and cyclosporin A treatment.
Topics: Anti-Bacterial Agents; Clarithromycin; Cyclosporine; Drug Interactions; Heart Transplantation; Humans; Immunosuppressive Agents; Liver Transplantation | 1998 |
Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Cyclosporine; Female; Follow-Up Studies; Graft Rejection; Humans; Hypertension; Immunosuppressive Agents; Kidney; Lung Transplantation; Male; Matched-Pair Analysis; Postoperative Complications; Pseudomonas Infections; Transplantation, Homologous | 2000 |
Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients.
Topics: Amoxicillin; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Clarithromycin; Cyclosporine; Dental Scaling; Female; Gingival Overgrowth; Heart Transplantation; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver Transplantation; Logistic Models; Male; Middle Aged; Mutation, Missense; Oral Hygiene; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prospective Studies | 2008 |
Interaction of clarithromycin with cyclosporine in cats: pharmacokinetic study and case report.
Topics: Animals; Cat Diseases; Cats; Clarithromycin; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male | 2012 |
Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs.
Topics: Administration, Oral; Animals; Biological Availability; Clarithromycin; Cyclosporine; Dogs; Dose-Response Relationship, Drug; Immunosuppression Therapy | 2014 |
Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Arginine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chickens; Clarithromycin; Cyclosporine; Cytochrome P-450 CYP3A Inhibitors; Drug Compounding; Gastrointestinal Tract; Hypromellose Derivatives; Ileum; Melanoma, Experimental; Mice; Nanoparticles; Paclitaxel; Particle Size; Rats, Sprague-Dawley; Skin Neoplasms; Surface Properties; Tumor Burden | 2014 |
Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges".
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Proliferation; Cell Survival; Clarithromycin; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythromycin; Female; Gene Expression; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Tumor Burden; Verapamil; Xenograft Model Antitumor Assays | 2015 |
[A CASE OF PULMONARY MYCOBACTERIUM ABSCESSUS INFECTION THAT DEVELOPED DURING IMMUNOSUPPRESSIVE THERAPY FOR MYASTHENIA GRAVIS WITH RECURRENT THYMOMA].
Topics: Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Cyclosporine; Drug Therapy, Combination; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Male; Middle Aged; Myasthenia Gravis; Mycobacterium Infections, Nontuberculous; Neoplasm Recurrence, Local; Thymoma; Thymus Neoplasms; Treatment Outcome | 2016 |
The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cyclosporine; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Male; Omeprazole; Proton Pump Inhibitors; Rats, Sprague-Dawley; Rifampin; Stomach Ulcer | 2021 |